Literature DB >> 19861670

Cardiovascular and noncardiovascular mortality among patients starting dialysis.

Dinanda J de Jager1, Diana C Grootendorst, Kitty J Jager, Paul C van Dijk, Lonneke M J Tomas, David Ansell, Frederic Collart, Patrik Finne, James G Heaf, Johan De Meester, Jack F M Wetzels, Frits R Rosendaal, Friedo W Dekker.   

Abstract

CONTEXT: Cardiovascular mortality is considered the main cause of death in patients receiving dialysis and is 10 to 20 times higher in such patients than in the general population.
OBJECTIVE: To evaluate if high overall mortality in patients starting dialysis is a consequence of increased cardiovascular mortality risk only or whether noncardiovascular mortality is equally increased. DESIGN, SETTING, AND PATIENTS: Using data from between January 1, 1994, and January 1, 2007, age-stratified mortality in a European cohort of adults starting dialysis and receiving follow-up for a mean of 1.8 (SD, 1.1) years (European Renal Association-European Dialysis and Transplant Association [ERA-EDTA] Registry [N = 123,407]) was compared with the European general population (Eurostat). MAIN OUTCOME MEASURES: Cause of death was recorded by ERA-EDTA codes in patients and matching International Statistical Classification of Diseases, 10th Revision codes in the general population. Standardized cardiovascular and noncardiovascular mortality rates, their ratio, difference, and relative excess of cardiovascular over noncardiovascular mortality were calculated.
RESULTS: Overall all-cause mortality rates in patients and the general population were 192 per 1000 person-years (95% confidence interval [CI], 190-193) and 12.055 per 1000 person-years (95% CI, 12.05-12.06), respectively. Cause of death was known for 90% of the patients and 99% of the general population. In patients, 16,654 deaths (39%) were cardiovascular and 21,654 (51%) were noncardiovascular. In the general population, 7,041,747 deaths (40%) were cardiovascular and 10,183,322 (58%) were noncardiovascular. Cardiovascular and noncardiovascular mortality rates in patients were respectively 38.1 per 1000 person-years (95% CI, 37.2-39.0) and 50.1 per 1000 person-years (95% CI, 48.9-51.2) higher than in the general population. On a relative scale, standardized cardiovascular and noncardiovascular mortality were respectively 8.8 (95% CI, 8.6-9.0) and 8.1 (95% CI, 7.9-8.3) times higher than in the general population. The ratio of these rates, ie, relative excess of cardiovascular over noncardiovascular mortality in patients starting dialysis compared with the general population, was 1.09 (95% CI, 1.06-1.12). Relative excess in a sensitivity analysis in which unknown/missing causes of death were regarded either as noncardiovascular or cardiovascular varied between 0.90 (95% CI, 0.88-0.93) and 1.39 (95% CI, 1.35-1.43).
CONCLUSION: Patients starting dialysis have a generally increased risk of death that is not specifically caused by excess cardiovascular mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19861670     DOI: 10.1001/jama.2009.1488

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  224 in total

1.  Myocardial perfusion SPECT "screening" at the start of dialysis.

Authors:  Sabha Bhatti; Abdul Hakeem
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

2.  Low health literacy associates with increased mortality in ESRD.

Authors:  Kerri L Cavanaugh; Rebecca L Wingard; Raymond M Hakim; Svetlana Eden; Ayumi Shintani; Kenneth A Wallston; Mary Margaret Huizinga; Tom A Elasy; Russell L Rothman; T Alp Ikizler
Journal:  J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 10.121

3.  Hyperhomocysteinemia: a renal and cardiovascular risk factor?

Authors:  Carmine Zoccali; Kitty J Jager
Journal:  Nat Rev Nephrol       Date:  2010-12       Impact factor: 28.314

4.  Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment.

Authors:  Ramin S Hastings; Judith S Hochman; Vladimir Dzavik; Gervasio A Lamas; Sandra A Forman; Francois Schiele; Lampros K Michalis; Dimitris Nikas; Joanna Jaroch; Harmony R Reynolds
Journal:  Am J Cardiol       Date:  2012-06-22       Impact factor: 2.778

5.  Initiation of dialysis: Trigger or cause of cardiovascular events?

Authors:  Wojciech Zareba
Journal:  Kidney Int       Date:  2015-11       Impact factor: 10.612

6.  Cocoa Flavanols: A Magic Potion for Protecting the Endothelium in Kidney Failure?

Authors:  Carmine Zoccali; Francesca Mallamaci
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-17       Impact factor: 8.237

7.  Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Authors:  Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo
Journal:  Br J Pharmacol       Date:  2020-08-23       Impact factor: 8.739

8.  Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial).

Authors:  Franklin Correa Barcellos; Bruno Pereira Nunes; Luciana Jorge Valle; Thiago Lopes; Bianca Orlando; Cintia Scherer; Marcia Nunes; Gabriela Araújo Duarte; Maristela Böhlke
Journal:  Infection       Date:  2016-08-29       Impact factor: 3.553

9.  Soluble TWEAK levels are independently associated with coronary artery disease severity in patients with stage 2-3 kidney disease.

Authors:  Alper Azak; Mehmet Fatih Akdoğan; Nazım Denizli; Bülent Huddam; Gülay Koçak; Murat Gücün; Mustafa Adem Tatlısu; Recep Demirci; Bilal Yılmaz; Mehmet Dikeç; Murat Bakırtaş; Ibrahim Akdağ; Murat Duranay
Journal:  Int Urol Nephrol       Date:  2013-09-17       Impact factor: 2.370

10.  Trends in in-hospital cardiopulmonary resuscitation and survival in adults receiving maintenance dialysis.

Authors:  Susan P Y Wong; William Kreuter; J Randall Curtis; Yoshio N Hall; Ann M O'Hare
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.